Teriparatide biosimilar - CinnaGen

Drug Profile

Teriparatide biosimilar - CinnaGen

Alternative Names: CinnoPar; rec Hu-PTH

Latest Information Update: 14 Apr 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator CinnaGen
  • Class Osteoporosis therapies; Peptide hormones; Skin disorder therapies
  • Mechanism of Action Osteogenesis stimulants; Parathyroid hormone receptor type 1 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Osteoporosis

Most Recent Events

  • 31 Dec 2013 Launched for Osteoporosis in Iran (SC)
  • 21 Oct 2013 Biomarkers information updated
  • 31 Dec 2010 Clinical trials in Osteoporosis in Iran (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top